ETF Holdings Breakdown of BCRX

News associated with BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 5.2% during the first quarter, HoldingsChannel reports. The fund owned 43,496 shares of the biotechnology company’s stock after acquiring an additional 2,146 shares during the quarter. SG Americas Securities LLC’s holdings in BioCryst Pharmaceuticals were worth $326,000 […] - 2025-06-26 07:58:58

Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $16.56

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year […] - 2025-06-25 05:44:54

Millennium Management LLC Sells 634,095 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Millennium Management LLC cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 44.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 790,105 shares of the biotechnology company’s stock after selling 634,095 shares during the quarter. Millennium Management LLC’s holdings […] - 2025-05-28 07:56:50

ProShare Advisors LLC Has $511,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

ProShare Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,004 shares of the biotechnology company’s stock after purchasing an additional 16,732 shares during the period. ProShare […] - 2025-05-27 08:36:51

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Man Group plc

Man Group plc increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 46.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,954 shares of the biotechnology company’s stock after purchasing an additional 28,481 shares during the period. Man Group […] - 2025-05-26 08:01:05

Wall Street Zen Upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) to “Strong-Buy”

Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a buy rating to a strong-buy rating in a research note published on Thursday. BCRX has been the subject of several other research reports. JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the […] - 2025-05-23 07:32:52

Lazard Asset Management LLC Buys 65,420 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Lazard Asset Management LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 68.1% during the fourth quarter, Holdings Channel reports. The fund owned 161,516 shares of the biotechnology company’s stock after acquiring an additional 65,420 shares during the quarter. Lazard Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $1,214,000 as […] - 2025-05-20 09:00:50

The Manufacturers Life Insurance Company Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

The Manufacturers Life Insurance Company decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 65.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 103,531 shares of the biotechnology company’s stock after selling 195,621 shares during the period. The Manufacturers Life Insurance Company’s holdings in […] - 2025-05-15 07:45:06

10,670 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,670 shares of the biotechnology company’s stock, valued at approximately $80,000. Several other institutional […] - 2025-05-14 07:26:53

Mariner LLC Grows Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mariner LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,258 shares of the biotechnology company’s stock after purchasing an additional 3,224 shares during the quarter. […] - 2025-05-09 08:08:42

BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $17.00 Price Target at Needham & Company LLC

BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Wedbush assumed coverage on […] - 2025-05-09 07:26:42

Tudor Investment Corp ET AL Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Tudor Investment Corp ET AL bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 99,450 shares of the biotechnology company’s stock, valued at approximately $748,000. A number of other institutional […] - 2025-05-08 09:44:51

JPMorgan Chase & Co. Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price lifted by JPMorgan Chase & Co. from $10.00 to $13.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 28.97% […] - 2025-05-08 08:04:48

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Earnings Beat

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report)’s stock price gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $8.93, but opened at $9.80. BioCryst Pharmaceuticals shares last traded at $10.03, with a volume of 5,915,215 shares changing hands. The biotechnology […] - 2025-05-07 05:20:57

Investors Buy Large Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 2,675 call options on the company. This represents an increase of approximately 174% compared to the average daily volume of 975 call options. BioCryst Pharmaceuticals Price Performance Shares of BCRX stock opened at […] - 2025-05-07 05:20:55

Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $16.13

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among […] - 2025-05-06 05:46:52

XTX Topco Ltd Sells 10,601 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

XTX Topco Ltd lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 33.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,069 shares of the biotechnology company’s stock after selling 10,601 shares during the period. XTX Topco Ltd’s holdings in […] - 2025-04-29 08:22:54

Russell Investments Group Ltd. Buys 12,941 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Russell Investments Group Ltd. boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 86.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,966 shares of the biotechnology company’s stock after acquiring an additional 12,941 shares during the quarter. Russell […] - 2025-04-25 08:54:49

Legal & General Group Plc Has $2.07 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Legal & General Group Plc raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 3.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 275,083 shares of the biotechnology company’s stock after acquiring an additional 10,199 shares during the period. Legal & General Group […] - 2025-04-25 08:12:54

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Invesco Ltd.

Invesco Ltd. boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 6.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,072,600 shares of the biotechnology company’s stock after purchasing an additional 67,492 shares during the period. Invesco Ltd. owned about 0.52% of BioCryst Pharmaceuticals […] - 2025-04-25 07:36:53

Renaissance Technologies LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Renaissance Technologies LLC lessened its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 7.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 545,021 shares of the biotechnology company’s stock after selling 44,059 shares during the quarter. Renaissance Technologies LLC’s holdings in BioCryst Pharmaceuticals were worth $4,099,000 at the end of the most […] - 2025-04-22 08:04:51

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 51.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 167,957 shares of the biotechnology company’s stock after buying an additional 56,930 shares during […] - 2025-04-15 08:35:00

Norges Bank Invests $3.95 Million in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Norges Bank acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 524,804 shares of the biotechnology company’s stock, valued at approximately $3,947,000. A number of other […] - 2025-04-11 08:06:51

Arrowstreet Capital Limited Partnership Sells 27,818 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Arrowstreet Capital Limited Partnership trimmed its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 403,412 shares of the biotechnology company’s stock after selling 27,818 shares during the quarter. Arrowstreet Capital Limited […] - 2025-04-10 08:45:21

Vanguard Group Inc. Has $164.62 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 7.8% during the fourth quarter, HoldingsChannel reports. The fund owned 21,890,422 shares of the biotechnology company’s stock after acquiring an additional 1,583,826 shares during the quarter. Vanguard Group Inc. owned 0.11% of BioCryst Pharmaceuticals worth $164,616,000 as of its most […] - 2025-04-07 09:35:13

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 7.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,731 shares of the biotechnology company’s stock after selling 7,755 shares during the quarter. […] - 2025-04-07 08:06:57

Schroder Investment Management Group Acquires 438,887 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Schroder Investment Management Group lifted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 523.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 522,657 shares of the biotechnology company’s stock after acquiring an additional 438,887 shares […] - 2025-04-06 09:32:56

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Position Increased by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 25.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 58,291 shares of the biotechnology company’s stock after purchasing an additional 11,711 shares during the period. Teacher Retirement System of Texas’ holdings in BioCryst Pharmaceuticals were worth […] - 2025-04-01 08:14:55

Cibc World Markets Corp Acquires New Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Cibc World Markets Corp bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 19,338 shares of the biotechnology company’s stock, valued at approximately $145,000. Several other hedge funds have also added […] - 2025-03-28 08:16:55

Charles Schwab Investment Management Inc. Has $14.89 Million Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Charles Schwab Investment Management Inc. increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,979,992 shares of the biotechnology company’s stock after buying an additional 91,998 shares during the quarter. […] - 2025-03-21 07:12:57

BCRX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	150,083	USD 1,449,802 -0.8%
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	19,540	USD 188,756
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	257,841	USD 2,490,744
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	105,271	USD 1,016,918
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	105,271	USD 1,016,918
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,126	USD 10,877
Total =		639,132	USD 6,174,015

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer